CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Cerus Corp is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Cerus Corp
1220 Concord Avenue
Phone: (925) 288-6000p:925 288-6000 CONCORD, CA  94520  United States Ticker: CERSCERS
Business Summary
Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYes---

Industries
SIC Code Description
3841 Surgical and medical instruments and apparatus
2836 Biological products, except diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Daniel N.Swisher 61 10/21/2013 6/27/2011
President, Chief Executive Officer, Director William M.Greenman 57 4/18/2011 9/1/2006
Chief Financial Officer, Vice President - Finance Kevin D.Green 52 2/1/2013 3/1/2009
10 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Cerus Europe B.V. Stationsstraat 79 D AMERSFOORT Netherlands

Business Names
Business Name
CERS
Cerus Corporation
Cerus Europe B.V

General Information
Number of Employees: 288 (As of 12/31/2023)
Outstanding Shares: 185,715,415 (As of 10/17/2024)
Shareholders: 116
Stock Exchange: NASD
Federal Tax Id: 680262011
Fax Number: (925) 288-6001
Email Address: ir@ceruscorp.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, November 21, 2024